Home > NEWS
Statement of SENOVA TECH 2019-03-19 Valsartan probe teaches FDA lesson about impurities in manufacturing It was a U.S. drugmaker that first alerted the FDA that the valsartan API it got from a Chinese ingredient maker contained a potentially dangerous impurity. And in the process of investigating, the FDA learned something it hadn’t known: that a combination of .. 2018-09-10 The European Commission has approved Pfizer’s Xeljanz as a treatment for psoriatic arthritis (PsA), significantly expanding the drug’s scope. European regulators are allowing use of Xeljanz (tofacitinib citrate) 5mg twice daily in combination with methotrexate for to treat active PsA in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying anti-rheumatic.. 2018-08-06 CPHI SHANGHAI 2018 WELCOME TO VISIT US IN CPHI SHANGHAI 2018 AT OUR BOOTH T2C01 2018-05-20 FDA approves Epclusa for treatment of chronic Hepatitis C virus infection FDA approves Epclusa for treatment of chronic Hepatitis C virus infection~The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients.. 2017-03-11 New US nod for Merck's nausea and vomiting drug US regulators have approved a single-dose version of Merck & Co's chemotherapy-associated nausea and vomiting drug Emend.The jab's use has been cleared, in combination with other anti-emetics, for the prevention of delayed nausea and vomiting in ad.. 2016-08-24
FirstPreviouscurrent 4/4 page total 24 records per page 6 Article234NextEnd
Copyright Copyright (C) 2015-2035 Senova Technology Co. Ltd.
Address: 311# in Building 3 of North Area, Dayuan Industry Park, Xili, Nanshan District of Shenzhen,China 518055  Tel: +86-0755-8670 3119 QQ: 530953397